pI: 6.29 |
Length (AA): 485 |
MW (Da): 53879 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
189 | 222 | 3dpr (E) | 4 | 39 | 50.00 | 0 | 0.27 | 0.432048 | 0.88 |
189 | 222 | 1ajj (A) | 6 | 39 | 47.00 | 0.00011 | 0.8 | 0.576248 | 0.34 |
193 | 481 | 2xrc (A) | 246 | 552 | 37.00 | 0 | 1 | 0.671107 | 0.76 |
250 | 484 | 4dgj (A) | 1 | 234 | 37.00 | 0 | 1 | 1.01554 | -1.1 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_126639)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_19535 | Trypsin family protein |
Caenorhabditis elegans | CELE_ZK546.15 | Protein TRY-1 |
Drosophila melanogaster | Dmel_CG17571 | CG17571 gene product from transcript CG17571-RB |
Drosophila melanogaster | Dmel_CG11836 | CG11836 gene product from transcript CG11836-RB |
Drosophila melanogaster | Dmel_CG4386 | CG4386 gene product from transcript CG4386-RA |
Drosophila melanogaster | Dmel_CG12350 | CG12350 gene product from transcript CG12350-RA |
Drosophila melanogaster | Dmel_CG18444 | alphaTrypsin |
Drosophila melanogaster | Dmel_CG30031 | CG30031 gene product from transcript CG30031-RA |
Drosophila melanogaster | Dmel_CG12351 | deltaTrypsin |
Drosophila melanogaster | Dmel_CG12385 | thetaTrypsin |
Drosophila melanogaster | Dmel_CG30028 | gammaTrypsin |
Drosophila melanogaster | Dmel_CG4316 | Stubble |
Drosophila melanogaster | Dmel_CG18735 | CG18735 gene product from transcript CG18735-RA |
Drosophila melanogaster | Dmel_CG4812 | CG4812 gene product from transcript CG4812-RA |
Drosophila melanogaster | Dmel_CG9564 | Trypsin 29F |
Drosophila melanogaster | Dmel_CG3355 | CG3355 gene product from transcript CG3355-RB |
Drosophila melanogaster | Dmel_CG18211 | betaTrypsin |
Drosophila melanogaster | Dmel_CG4613 | CG4613 gene product from transcript CG4613-RC |
Drosophila melanogaster | Dmel_CG30025 | CG30025 gene product from transcript CG30025-RA |
Drosophila melanogaster | Dmel_CG18681 | epsilonTrypsin |
Homo sapiens | ENSG00000275896 | protease, serine, 2 (trypsin 2) |
Homo sapiens | 102725325 | putative trypsin-6-like |
Homo sapiens | ENSG00000204983 | protease, serine, 1 (trypsin 1) |
Homo sapiens | ENSG00000010438 | protease, serine, 3 |
Loa Loa (eye worm) | LOAG_16157 | hypothetical protein |
Loa Loa (eye worm) | LOAG_10674 | hypothetical protein |
Mus musculus | ENSMUSG00000056399 | protease, serine 34 |
Mus musculus | ENSMUSG00000029882 | RIKEN cDNA 2210010C04 gene |
Mus musculus | ENSMUSG00000054106 | trypsin 4 |
Mus musculus | ENSMUSG00000036938 | trypsin 5 |
Mus musculus | ENSMUSG00000071517 | predicted gene 10334 |
Mus musculus | ENSMUSG00000058119 | predicted gene 5771 |
Mus musculus | ENSMUSG00000071519 | protease, serine 3 |
Mus musculus | ENSMUSG00000062751 | protease, serine 1 (trypsin 1) |
Mus musculus | ENSMUSG00000071521 | trypsin 10 |
Mus musculus | ENSMUSG00000057163 | protease, serine 2 |
Onchocerca volvulus | OVOC11330 |
|
Onchocerca volvulus | OVOC11328 |
|
Schistosoma japonicum | Sjp_0208500 | ko:K09639 transmembrane protease, serine 8, putative |
Schistosoma japonicum | Sjp_0012180 | ko:K09639 transmembrane protease, serine 8, putative |
Schistosoma mansoni | Smp_030350 | subfamily S1A unassigned peptidase (S01 family) |
Schistosoma mansoni | Smp_129230 | subfamily S1A unassigned peptidase (S01 family) |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
CELE_ZK546.15 | Caenorhabditis elegans | embryonic lethal | wormbase |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | protease, serine, 1 (trypsin 1) | Compounds | References |
Homo sapiens | protease, serine, 2 (trypsin 2) | Compounds | References |
Rattus norvegicus | Anionic trypsin-1 | Compounds | References |
Rattus norvegicus | Trypsin II | Compounds | References |
Sus scrofa | Trypsin | Compounds | References |
Homo sapiens | protease, serine, 3 | Compounds | References |
Bos taurus | Trypsin I | Compounds | References |
Bos taurus | Trypsin II | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Mast cell protease 3 | 247 aa | 28.6% | 210 aa | Compounds | References |
Sus scrofa | Glandular kallikrein | 246 aa | 30.8% | 221 aa | Compounds | References |
Rattus norvegicus | Tryptase alpha/beta-1 | 273 aa | 35.4% | 254 aa | Compounds | References |
Rattus norvegicus | Elastase 2A | 271 aa | 34.4% | 256 aa | Compounds | References |
Oryctolagus cuniculus | Thrombin | 235 aa | 32.5% | 231 aa | Compounds | References |
Canis lupus familiaris | Coagulation factor X | 159 aa | 32.7% | 165 aa | Compounds | References |
Sus scrofa | Elastase 2A | 269 aa | 34.7% | 248 aa | Compounds | References |
Bos taurus | Alpha-chymotrypsin | 245 aa | 33.5% | 239 aa | Compounds | References |
Bos taurus | Beta-chymotrypsin | 245 aa | 34.3% | 239 aa | Compounds | References |
Sus scrofa | Pancreatic elastase | 269 aa | 34.7% | 248 aa | Compounds | References |
Sus scrofa | Elastase 1 | 266 aa | 33.2% | 247 aa | Compounds | References |
Canis lupus familiaris | Tryptase | 275 aa | 35.5% | 248 aa | Compounds | References |